TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?
Emmanuelle Samalin1, Antoine Adenis2
1Department of Medical Oncology, Montpellier Cancer Institute, Montpellier 34298, France; IGF, CNRS, INSERM, Montpellier University, Montpellier, France.
The Lancet. Oncology
|July 20, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K